Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Oral Communications

Oral Communications 7: Pituitary and Neuroendocrinology 2

ea0081oc7.1 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Splicing factor 3 subunit B1 (SF3B1) inhibition in PRL-secreting PitNETs and cross-talk with dopamine receptor type 2 (DRD2)

Di Muro Genesio , Mangili Federica , Barbieri Anna Maria , Esposito Emanuela , Treppiedi Donatella , Arlati Federico , Catalano Rosa , Marra Giusy , Nozza Emma , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Somatic mutations in splicing factor 3 subunit B1 (SF3B1) were found in about 20% of PRL-secreting PitNETs. SF3B1 is involved in pre-mRNA splicing and required for assembly of the U2 complex, which is critical for branch site recognition and the early stages of spliceosome assembly. Patients with mutant prolactinomas showed higher PRL levels and shorter progression-free survival compared to wild-type patients. Aims of the present study were: 1) to characterize the genetic prof...

ea0081oc7.2 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Kisspeptin administration has therapeutic potential for men with low sexual desire by increasing penile tumescence and sexual brain processing

Mills Edouard , Ertl Natalie , Wall Matt B , Thurston Layla , Yang Lisa , Suladze Sofiya , Hunjan Tia , Phylactou Maria , Patel Bijal , Muzi Beatrice , Ettehad Dena , Howard Jonathan , Rabiner Eugenii A , Bech Paul , Abbara Ali , Goldmeier David , Comninos Alexander , Dhillo Waljit

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with dysfunctional brain activation in regions governing sexual responses, resulting in a deficiency/absence of sexual desire with marked distress. It affects up to 8% of men with detrimental effects on quality of life, interpersonal relationships and fertility, but so far has no licensed treatment options. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role ...

ea0081oc7.3 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Clinical practice outcomes from 107 patients with Cushing’s syndrome treated with osilodrostat in France

Dormoy Alexandre , Haissaguerre Magalie , Drui Dephine , Demarquet Lea , Do Cao Christine , Guignat Laurence , Vaillant C , Papegaey Anne-Cecile , Raznik Yves , Bras Maelle Le , Salenave S , Raingeard Isabelle , Tauveron I , Christine Vantyghem Marie , Francois M , Delemer B , Luca Florina , Mayer Anne , Petit Jean-Michel , Baudin Eric , Chanson Philippe , Castinetti Frederic , Raverot Gerald , Chabre Olivier , Tabarin Antoine , Young Jacques

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....

ea0081oc7.4 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

HPLC-MSMS steroidogenic profiles in ACTH-dependent Cushing Syndrome patients treated by osilodrostat or metyrapone suggest differences in the spectrum of steroidogenic enzyme inhibition between the two CYP11B1 inhibitors in clinical care

Fideline Bonnet , Poirier Jonathan , Vaczlavik Anna , Laguillier-Morizot Christelle , Blanchet Benoit , Guignat Laurence , Bessiene Laura , Bricaire Leopoldine , Groussin Lionel , Assie Guillaume , Guibourdenche Jean , Bertherat Jerome

Introduction: Osilodrostat is a new 11 ß-hydroxylase inhibitor with a mode of action analogue to metyrapone. It has become increasingly used in recent years for treatment of Cushing’s Syndrome (CS). However, few in vivo studies are currently available to accurately compare both drugs characteristics. The objective of our study was to compare steroidogenic profiles in patients treated by either Osilodrostat or Metyrapone for ACTH-dependent CS.Me...

ea0081oc7.5 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Epigenomic and somatic mutation profile of pituitary adenomas (PAs)/ pituitary neuroendocrine tumors (PitNETs)

Guaraldi Federica , Morandi Luca , Zoli Matteo , Righi Alberto , Evangelisti Stefania , Tonon Caterina , Mazzatenta Diego , Asioli Sofia

Background: Pituitary adenomas (PAs)/Pituitary Neuroendocrine Tumors (PitNETs) are a complex and heterogeneous group of lesions. Genetic and epigenetic studies have been performed to identify predictors of treatment outcome.Study aim: To profile clinically non-aggressive (NA) and aggressive (A) PAs/PitNETs, and carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, miRNA/lncRNA-post-transcript...

ea0081oc7.6 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

A tumor-borne Angpt2/Tie2 autostimulatory loop controls tumorigenesis

Pellegata Natalia , Minaskan Ninelia , Gulde Sebastian , Mohr Hermine , Geppert Julia , Rohm Maria , Vitale Giovanni , Gaudenzi Germano , Dicitore Alessandra , Franz Schilling , Schillmaier Mathias , Eisenhofer Graeme , Herzig Stephan , Roncaroli Federico , Honegger Jurgen

Background: Invasive nonfunctioning (NF) pituitary neuroendocrine tumors (PitNETs) are non-resectable neoplasms associated to frequent relapse and significant comorbidities. As current treatments often fail against NF-PitNETs, identifying actionable therapeutic targets is essential. We focused on the angiopoietin-2 (Angpt2)/Tie2 axis, usually active in endothelial cells (ECs).Methods: ANGPT2 plasma levels in NF-PitNET patients and healthy controls were m...